Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07287917Phase 1Recruiting

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Role: lead

NCT06465199Phase 1Recruiting

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Role: collaborator

NCT05500508Phase 1Terminated

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Role: lead

NCT03536728Phase 1Completed

Oral AMXT 1501 Dicaprate in Combination With DFMO

Role: lead

NCT03077477Phase 1Withdrawn

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

Role: lead

All 5 trials loaded